Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Compass Therapeutics, Inc. - Common Stock (NQ:CMPX)

4.035 +0.215 (+5.63%)
Streaming Delayed Price Updated: 2:25 PM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Compass Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Compass Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
From Compass Therapeutics, Inc.
Via Business Wire
3 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Compass Pathways (NASDAQ:CMPS) shares rose 18.43% to $51.0 during Tuesday's pre-market session. The company's market cap stands at $2.1 billion. As per the... 
Via Benzinga
32 Stocks Moving in Tuesday's Pre-Market Session
Gainers Dover Motorsports, Inc. (NYSE: DVD) rose 57% to $3.58 in pre-market trading. Luminar Technologies, Inc. (NASDAQ: LAZR) rose 54.2% to $26.98 in pre-market trading after... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion... 
Via Benzinga
71 Biggest Movers From Yesterday
Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales... 
Via Benzinga
Mid-Morning Market Update: Markets Edge Higher; Pfizer Boosts FY21 Outlook
Following the market opening Tuesday, the Dow traded up 0.08% to 35,942.26 while the NASDAQ rose 0.18% to 15,624.19. The S&P also rose, gaining 0.24% to 4,624.80. The U.S. has... 
Via Benzinga
Topics Stocks
Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market
From Compass Therapeutics, Inc.
Via Business Wire
Compass Therapeutics Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market
From Compass Therapeutics, Inc.
Via Business Wire
Compass Reports the Advancement of CTX-009, a Bispecific Antibody, to Phase 2a Development in Patients with Biliary Tract Cancers (BTC), and the Clearance of a Key Clinical Hurdle
From Compass Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021
Upgrades For Iridium Communications Inc (NASDAQ:IRD... 
Via Benzinga
CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Compass Therapeutics, Inc.
Via Business Wire
Compass Therapeutics and ABL Bio Announce Presentation of CTX-009 Clinical Data as a Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Compass Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Compass Therapeutics to Present at the Citi 16th Annual Biopharma Virtual Conference
From Compass Therapeutics, Inc.
Via Business Wire
Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.
From Compass Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.